Low dose ursodeoxycholic acid at bedtime and at mealtimes

Effect on mass of lipids within the gallbladder and on gallstone dissolution rate

G. Galatola, R. P. Jazrawi, T. C. Northfield

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To compare the effect of bedtime and mealtime administration of low dose ursodeoxycholic acid (UDCA) (3-5 mg/kg per day) in gallstone patients on cholesterol saturation index, total mass of biliary lipids within the gallbladder and gallstone dissolution rate. Design: Patients were randomly allocated to either bedtime or mealtime UDCA at a dose similar to that used for gallstone dissolution in combination with chenodeoxycholic acid (CDCA). Methods: In 18 patients with radiolucent gallstones in radiologically functioning gallbladders we measured the total mass of biliary lipids within the gallbladder before and after 1 month of UDCA therapy by gallbladder bile sampling and cholescintigraphy; gallstone dissolution rate was measured after 6 and 12 months of therapy. Results: The dissolution rate was faster for the bedtime regimen (n = 9) than for the mealtime regimen (n = 9), both at 6 months (medians: 40 versus 0%, P <0.05) and at 12 months (70 versus 0%, P <0.05). In the whole group (n = 12), the saturation index was significantly reduced during therapy: this was caused by significantly reduced cholesterol mass within the gallbladder, without changes in the bile acid or phospholipid masses. There was no difference between the two dose timings for saturation index or for the lipid masses within the gallbladder. Conclusions: Using a low dose of UDCA, bedtime administration is more efficacious than mealtime administration for cholesterol gallstone dissolution; the reduction in saturation index is due only to a reduction of cholesterol mass within the gallbladder. These findings suggest that combination therapy involving low doses of both UDCA and CDCA should also be given at bedtime.

Original languageEnglish
Pages (from-to)301-306
Number of pages6
JournalEuropean Journal of Gastroenterology and Hepatology
Volume4
Issue number4
Publication statusPublished - 1992

Fingerprint

Ursodeoxycholic Acid
Gallstones
Gallbladder
Meals
Lipids
Cholesterol
Chenodeoxycholic Acid
Therapeutics
Bile Acids and Salts
Bile
Phospholipids

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{570675a6f06c4034b1032d1995cda8e0,
title = "Low dose ursodeoxycholic acid at bedtime and at mealtimes: Effect on mass of lipids within the gallbladder and on gallstone dissolution rate",
abstract = "Objective: To compare the effect of bedtime and mealtime administration of low dose ursodeoxycholic acid (UDCA) (3-5 mg/kg per day) in gallstone patients on cholesterol saturation index, total mass of biliary lipids within the gallbladder and gallstone dissolution rate. Design: Patients were randomly allocated to either bedtime or mealtime UDCA at a dose similar to that used for gallstone dissolution in combination with chenodeoxycholic acid (CDCA). Methods: In 18 patients with radiolucent gallstones in radiologically functioning gallbladders we measured the total mass of biliary lipids within the gallbladder before and after 1 month of UDCA therapy by gallbladder bile sampling and cholescintigraphy; gallstone dissolution rate was measured after 6 and 12 months of therapy. Results: The dissolution rate was faster for the bedtime regimen (n = 9) than for the mealtime regimen (n = 9), both at 6 months (medians: 40 versus 0{\%}, P <0.05) and at 12 months (70 versus 0{\%}, P <0.05). In the whole group (n = 12), the saturation index was significantly reduced during therapy: this was caused by significantly reduced cholesterol mass within the gallbladder, without changes in the bile acid or phospholipid masses. There was no difference between the two dose timings for saturation index or for the lipid masses within the gallbladder. Conclusions: Using a low dose of UDCA, bedtime administration is more efficacious than mealtime administration for cholesterol gallstone dissolution; the reduction in saturation index is due only to a reduction of cholesterol mass within the gallbladder. These findings suggest that combination therapy involving low doses of both UDCA and CDCA should also be given at bedtime.",
author = "G. Galatola and Jazrawi, {R. P.} and Northfield, {T. C.}",
year = "1992",
language = "English",
volume = "4",
pages = "301--306",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Low dose ursodeoxycholic acid at bedtime and at mealtimes

T2 - Effect on mass of lipids within the gallbladder and on gallstone dissolution rate

AU - Galatola, G.

AU - Jazrawi, R. P.

AU - Northfield, T. C.

PY - 1992

Y1 - 1992

N2 - Objective: To compare the effect of bedtime and mealtime administration of low dose ursodeoxycholic acid (UDCA) (3-5 mg/kg per day) in gallstone patients on cholesterol saturation index, total mass of biliary lipids within the gallbladder and gallstone dissolution rate. Design: Patients were randomly allocated to either bedtime or mealtime UDCA at a dose similar to that used for gallstone dissolution in combination with chenodeoxycholic acid (CDCA). Methods: In 18 patients with radiolucent gallstones in radiologically functioning gallbladders we measured the total mass of biliary lipids within the gallbladder before and after 1 month of UDCA therapy by gallbladder bile sampling and cholescintigraphy; gallstone dissolution rate was measured after 6 and 12 months of therapy. Results: The dissolution rate was faster for the bedtime regimen (n = 9) than for the mealtime regimen (n = 9), both at 6 months (medians: 40 versus 0%, P <0.05) and at 12 months (70 versus 0%, P <0.05). In the whole group (n = 12), the saturation index was significantly reduced during therapy: this was caused by significantly reduced cholesterol mass within the gallbladder, without changes in the bile acid or phospholipid masses. There was no difference between the two dose timings for saturation index or for the lipid masses within the gallbladder. Conclusions: Using a low dose of UDCA, bedtime administration is more efficacious than mealtime administration for cholesterol gallstone dissolution; the reduction in saturation index is due only to a reduction of cholesterol mass within the gallbladder. These findings suggest that combination therapy involving low doses of both UDCA and CDCA should also be given at bedtime.

AB - Objective: To compare the effect of bedtime and mealtime administration of low dose ursodeoxycholic acid (UDCA) (3-5 mg/kg per day) in gallstone patients on cholesterol saturation index, total mass of biliary lipids within the gallbladder and gallstone dissolution rate. Design: Patients were randomly allocated to either bedtime or mealtime UDCA at a dose similar to that used for gallstone dissolution in combination with chenodeoxycholic acid (CDCA). Methods: In 18 patients with radiolucent gallstones in radiologically functioning gallbladders we measured the total mass of biliary lipids within the gallbladder before and after 1 month of UDCA therapy by gallbladder bile sampling and cholescintigraphy; gallstone dissolution rate was measured after 6 and 12 months of therapy. Results: The dissolution rate was faster for the bedtime regimen (n = 9) than for the mealtime regimen (n = 9), both at 6 months (medians: 40 versus 0%, P <0.05) and at 12 months (70 versus 0%, P <0.05). In the whole group (n = 12), the saturation index was significantly reduced during therapy: this was caused by significantly reduced cholesterol mass within the gallbladder, without changes in the bile acid or phospholipid masses. There was no difference between the two dose timings for saturation index or for the lipid masses within the gallbladder. Conclusions: Using a low dose of UDCA, bedtime administration is more efficacious than mealtime administration for cholesterol gallstone dissolution; the reduction in saturation index is due only to a reduction of cholesterol mass within the gallbladder. These findings suggest that combination therapy involving low doses of both UDCA and CDCA should also be given at bedtime.

UR - http://www.scopus.com/inward/record.url?scp=0026516161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026516161&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 301

EP - 306

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 4

ER -